ReviewCell communication and signaling : CCS2026
3D chromatin structure remodelling in cancer.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Three-dimensional (3D) chromatin structure is crucial for gene regulation and cellular identity, with alterations in this structure being closely associated with tumor development. Although the research of tumor genomics has made significant progress in the past decade, the mechanism of 3D chromatin structure in tumorigenesis is not completely clear. Recent studies have shown that the distortion of chromatin spatial conformation has become one of the core factors driving normal cell carcinogenesis by changing the gene regulatory network. Abnormal high-order chromatin organization leads to abnormal activation of oncogenes or silencing of tumor suppressor genes. This 3D chromatin disorder has been confirmed to be directly related to the phenotypic plasticity of a variety of tumors. Therefore, the dynamic changes of 3D chromatin structure play a key role in the occurrence and development of tumors, especially for malignant tumors with difficult diagnosis and lack of treatment. This article provides an overview of hierarchical alterations in cancer 3D chromatin structure, the mechanisms governing these changes, recent advances in detection technologies, and emerging therapeutic strategies. The unique 3D chromatin variation pattern in cancers may become a new biomarker and provide a theoretical basis for epigenetic therapy targeting chromatin spatial organization. In the future, integrating multi-omics data to develop specific drugs for key nodes of the 3D chromatin and establishing an early diagnosis system based on spatial chromatin characteristics will become an important direction to break through the bottleneck of cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.